INS and Other metabolic disease: When treating metabolic disorders with IGF-1, phase II trials until now conducted by Clemmons et al. including adult patients with either T1D or T2D treating with mecasermin rinfabate (1–2 mg/kg/day for 14 days) showed lowered exogenous insulin requirements while improving glycaemic control.